Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...

The Danish pharmaceutical giant is licensing global rights to LX9851, a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Novo Nordisk is licensing Lexicon Pharmaceuticals experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...